ALVO Quote, Financials, Valuation and Earnings

Ardelyx has a net margin of 82.61% compared to Alvotech's net margin of -55.52%. Alvotech's return on equity of -- beat Ardelyx's return on equity of -34.68%.

Alvotech has a consensus price target of $17.90, signalling upside risk potential of 105.04%. On the other hand Ardelyx has an analysts' consensus of $10.91 which suggests that it could grow by 141.35%. Given that Ardelyx has higher upside potential than Alvotech, analysts believe Ardelyx is more attractive than Alvotech.

Alvotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ardelyx has a beta of 0.605, suggesting its less volatile than the S&P 500 by 39.538%.

Alvotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ardelyx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alvotech pays -- of its earnings as a dividend. Ardelyx pays out -- of its earnings as a dividend.

Alvotech quarterly revenues are $132.8M, which are larger than Ardelyx quarterly revenues of $74.1M. Alvotech's net income of $109.7M is higher than Ardelyx's net income of -$41.1M. Notably, Alvotech's price-to-earnings ratio is 23.59x while Ardelyx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alvotech is 4.25x versus 2.96x for Ardelyx. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of 82.61% compared to Alvotech's net margin of 32.71%. Alvotech's return on equity of -- beat Merck &'s return on equity of 39.02%.

Alvotech has a consensus price target of $17.90, signalling upside risk potential of 105.04%. On the other hand Merck & has an analysts' consensus of $101.79 which suggests that it could grow by 24.86%. Given that Alvotech has higher upside potential than Merck &, analysts believe Alvotech is more attractive than Merck &.

Alvotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Merck & has a beta of 0.389, suggesting its less volatile than the S&P 500 by 61.063%.

Alvotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.93% to investors and pays a quarterly dividend of $0.81 per share. Alvotech pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Alvotech quarterly revenues are $132.8M, which are smaller than Merck & quarterly revenues of $15.5B. Alvotech's net income of $109.7M is lower than Merck &'s net income of $5.1B. Notably, Alvotech's price-to-earnings ratio is 23.59x while Merck &'s PE ratio is 11.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alvotech is 4.25x versus 3.24x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

AVITA Medical has a net margin of 82.61% compared to Alvotech's net margin of -74.86%. Alvotech's return on equity of -- beat AVITA Medical's return on equity of -415.55%.

Alvotech has a consensus price target of $17.90, signalling upside risk potential of 105.04%. On the other hand AVITA Medical has an analysts' consensus of $16.95 which suggests that it could grow by 211.28%. Given that AVITA Medical has higher upside potential than Alvotech, analysts believe AVITA Medical is more attractive than Alvotech.

Alvotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AVITA Medical has a beta of 1.518, suggesting its more volatile than the S&P 500 by 51.797%.

Alvotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AVITA Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alvotech pays -- of its earnings as a dividend. AVITA Medical pays out -- of its earnings as a dividend.

Alvotech quarterly revenues are $132.8M, which are larger than AVITA Medical quarterly revenues of $18.5M. Alvotech's net income of $109.7M is higher than AVITA Medical's net income of -$13.9M. Notably, Alvotech's price-to-earnings ratio is 23.59x while AVITA Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alvotech is 4.25x versus 1.97x for AVITA Medical. Usually stocks with elevated PS ratios are considered overvalued.

TG Therapeutics has a net margin of 82.61% compared to Alvotech's net margin of 4.19%. Alvotech's return on equity of -- beat TG Therapeutics's return on equity of 19.78%.

Alvotech has a consensus price target of $17.90, signalling upside risk potential of 105.04%. On the other hand TG Therapeutics has an analysts' consensus of $40.50 which suggests that it could grow by 3.34%. Given that Alvotech has higher upside potential than TG Therapeutics, analysts believe Alvotech is more attractive than TG Therapeutics.

Alvotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison TG Therapeutics has a beta of 1.913, suggesting its more volatile than the S&P 500 by 91.257%.

Alvotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alvotech pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

Alvotech quarterly revenues are $132.8M, which are larger than TG Therapeutics quarterly revenues of $120.9M. Alvotech's net income of $109.7M is higher than TG Therapeutics's net income of $5.1M. Notably, Alvotech's price-to-earnings ratio is 23.59x while TG Therapeutics's PE ratio is 163.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alvotech is 4.25x versus 16.31x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.